A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) (NCT07268638)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Who can join: Review the eligibility criteria below.
Location: Investigator Site #2 — Chula Vista, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Investigator Site #2 — Chula Vista, California
- Investigator Site #14 — Los Angeles, California
- Investigator Site #12 — San Dimas, California
- Investigator Site #13 — Arvada, Colorado
- Investigator Site #17 — Boca Raton, Florida
- Investigator Site #6 — Coral Springs, Florida
- Investigator Site #25 — Hialeah, Florida
- Investigator Site #7 — Miami, Florida
- Investigator Site #8 — Orlando, Florida
- Investigator Site # 1 — Lawrenceville, Georgia
- Investigator Site #3 — Chicago, Illinois
- Investigator Site #11 — Louisville, Kentucky
- Investigator Site #24 — Worcester, Massachusetts
- Investigator Site #15 — Livonia, Michigan
- Investigator Site #10 — Pontiac, Michigan
- Investigator Site #16 — New Bern, North Carolina
- Investigator Site #20 — Cleveland, Ohio
- Investigator Site #19 — Bridgeville, Pennsylvania
- Investigator Site #22 — Butler, Pennsylvania
- Investigator Site #23 — Goose Creek, South Carolina
- Investigator Site #4 — Chattanooga, Tennessee
- Investigator Site #5 — Arlington, Texas
- Investigator Site #21 — Dallas, Texas
- Investigator Site #9 — Dallas, Texas
- Investigator Site #18 — Houston, Texas
📞 Contact the Study Coordinator
Phone: (617) 844-6128
Email: trials@akebia.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Focal Segmental Glomerulosclerosis
- Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure — Boston, Massachusetts
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases — Bethesda, Maryland
- Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children — Loma Linda, California
- Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System — Loma Linda, California
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — Los Angeles, California
Explore by condition: All Focal Segmental Glomerulosclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.